[NFS-02-5] 神経疾患を標的にしたDNA/RNA2本鎖ヘテロ核酸の開発
Dr. Yokota graduated from Tokyo Medical and Dental University in 1984, and and studied as a research fellow in Bredesen's lab in Burham Institute and Buck Center for Aging Research (CA, USA) in 1999-2000. He accepted a position as Professor in 2010, and Chairman of Department Neurology and Neurological Science, Tokyo Medical and Dental University. He has been a president of Nucleic Acid Therapeutic Society of Japan since 2018 and BOD member of Oligonucleotide Therapeutic Society (OTS) since 2016. He also started “RENA Therapeutics” and ‘Braizon Therapeuttics’. His group has developed DNA/RNA oligonucleotide (HDO) as a third class of oligonucleotide drug which is highly potent and can regulate extra-hepatic organs including CNS through BBB by systemic administration.
抄録パスワード認証
パスワードは「第64回日本神経学会学術大会プログラム・抄録集」の18ページに記載してあります。